Nab-paclitaxel vs paclitaxel liposome for advanced breast cancer: real-world efficacy and safety analysis
Nab-paclitaxel or paclitaxel liposomes remain significantly effective in patients with advanced breast cancer who have failed first or multiline therapy. Nab-paclitaxel is superior to paclitaxel liposome in efficacy evaluation, paclitaxel liposome is superior to nab-paclitaxel in survival outcome.
Authors
- Jisheng Chen (ORCID: https://orcid.org/0000-0003-3514-9086)
- Mengting Li (ORCID: https://orcid.org/0000-0001-5894-757X)
Institutions
- The First People's Hospital of Shunde (CN)
- First People's Hospital of Foshan (CN)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1080/14796694.2025.2574833
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00